DeepMed Research

ONENESS BIOTECH CO., LTD.

🇹🇼Taiwan

Country: 🇹🇼Taiwan

Ownership: Public

Established: 2008-06-01

Employees: 51

Market Cap: -

Website: http://www.onenessbio.com.tw

Clinical Trials

Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers

Phase 2

Recruiting

Conditions: Diabetic Foot Ulcer

Interventions: Drug: Xianglei Tangzu Gao
Other: Vehicle Cream

First Posted Date: 2024-08-01

Last Posted Date: 2024-12-20

Lead Sponsor: Oneness Biotech Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT06531512

Locations: 🇨🇳
Jiangmen Central Hospital, Jiangmen, Guangdong, China
🇨🇳
The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China
🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

and more 9 locations

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Phase 2

Recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo
Drug: FB825

First Posted Date: 2024-05-03

Last Posted Date: 2025-04-01

Lead Sponsor: Oneness Biotech Co., Ltd.

Target Recruit Count: 90

Registration Number: NCT06397911

Locations: 🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸
California Allergy and Asthma Medical Group, Los Angeles, California, United States
🇺🇸
University of California, Davis Health, Department of Dermatology, Sacramento, California, United States

and more 12 locations

A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults

Phase 1

Active, not recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: FB825 or Placebo in subcutaneous route
Drug: FB825 in intravenous route

First Posted Date: 2023-07-19

Last Posted Date: 2024-01-26

Lead Sponsor: Oneness Biotech Co., Ltd.

Target Recruit Count: 22

Registration Number: NCT05952986

Locations: 🇺🇸
Phase I center, Anaheim, California, United States

A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients

Phase 2

Active, not recruiting

Conditions: Mild to Moderate COVID-19

Interventions: Drug: MBS-COV
Drug: Placebo

First Posted Date: 2023-07-12

Last Posted Date: 2024-06-25

Lead Sponsor: Oneness Biotech Co., Ltd.

Target Recruit Count: 135

Registration Number: NCT05941793

Locations: 🇨🇳
Taipei Municipal Wanfang Hospital, Taipei, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇺🇸
Velocity Clinical Research, Salt Lake City, Utah, United States

and more 2 locations

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants

Phase 1

Completed

Conditions: Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)

Interventions: Other: Placebo
Drug: MBS-COV

First Posted Date: 2023-01-10

Last Posted Date: 2025-03-30

Lead Sponsor: Oneness Biotech Co., Ltd.

Target Recruit Count: 44

Registration Number: NCT05677893

Locations: 🇺🇸
Phase I Unit, Los Angeles, California, United States

Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B)

Phase 4

Terminated

Conditions: Diabetic Foot Ulcer (DFU)

Interventions: Drug: Fespixon Cream

First Posted Date: 2022-06-29

Last Posted Date: 2024-05-16

Lead Sponsor: Oneness Biotech Co., Ltd.

Target Recruit Count: 3

Registration Number: NCT05438251

Locations: 🇨🇳
China Medical University Hospital, Taichung, Taiwan

A Research Study to Evaluate the Safety and Potential Efficacy of ON101 Cream for the Treatment of Venous Leg Ulcers.

Phase 4

Terminated

Conditions: Venous Leg Ulcers (VLU)

Interventions: Drug: ON101 Cream

First Posted Date: 2022-04-12

Last Posted Date: 2025-03-12

Lead Sponsor: Oneness Biotech Co., Ltd.

Target Recruit Count: 9

Registration Number: NCT05322525

Locations: 🇨🇳
Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan

Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer

Conditions: Diabetic Foot Ulcer

Interventions: Drug: ON101 Cream

First Posted Date: 2021-11-26

Last Posted Date: 2021-12-08

Lead Sponsor: Oneness Biotech Co., Ltd.

Target Recruit Count: 176

Registration Number: NCT05135130

Locations: 🇨🇳
China Medical University Hospital, Taichung City, Taiwan

Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Biological: FB825

First Posted Date: 2021-09-28

Last Posted Date: 2022-04-04

Lead Sponsor: Oneness Biotech Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT05059509

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma

Phase 2

Recruiting

Conditions: Severe Asthma

Interventions: Biological: FB704A placebo
Biological: FB704A

First Posted Date: 2021-08-24

Last Posted Date: 2024-01-26

Lead Sponsor: Oneness Biotech Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT05018299

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳
NTUH Hsin-Chu Branch, Hsinchu, Taiwan
🇨🇳
China Medical University Hospital, Taichung city, Taiwan

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy